<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) JUNE 10, 1996
ENZON, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 0-12957 22-237286
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification)
20 KINGSBRIDGE ROAD, PISCATAWAY, NEW JERSEY 08854
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (908) 980-4500
(Former name or former address, if changed since last report)
<PAGE>
ITEM 5. OTHER EVENTS
Enzon, Inc. ("Enzon" or the "Company") announced that it has
exercised 150,000 warrants to purchase common stock of Neoprobe Corporation
and sold the stock for a net profit of approximately $1 million, after
payment to Neoprobe of the aggregate average exercise price of $10.50 per
share. The warrants were part of the compensation Enzon received for
licensing its Single-Chain Antigen-Binding (SCA(R)) protein technology to
Neoprobe for use with Neoprobe's Radioimmunoguided Surgery (RIGS(R))
product under the license agreement originally signed in 1992. The
warrants were due to expire in 1996. Enzon will also be entitled to
receive additional payments per product upon the achievement of specified
development milestones and royalties on sales of any future products
developed by Neoprobe that utilize Enzon's SCA technology.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated: June 24, 1996
ENZON, INC.
(Registrant)
By: /s/KENNETH J. ZUERBLIS
Kenneth J. Zuerblis
Vice President, Finance
and Chief Financial
Officer